share_log

啓明醫療-B：(1) 須予披露交易有關建造及開發項目土地；及(2) 繼續暫停買賣

VENUS MEDTECH-B: (1) DISCLOSEABLE TRANSACTION IN RELATION TO THE CONSTRUCTION AND DEVELOPMENT OF THE PROJECT LAND; AND (2) CONTINUED SUSPENSION OF TRADING

香港交易所 ·  Feb 25 05:10
Summary by Moomoo AI
啟明醫療-B（股份代號：2500）宣布，公司已於2021年9月通過公開招標獲得杭州市規劃和自然資源局項目土地的使用權，該土地位於杭州國家高新技術產業開發區，計劃用於開發啟明醫療生命健康產業園。2022年11月17日，啟明醫療與中建一局集團簽訂建造合約，合約總額約為人民幣11.82億元，該合約因最高適用百分比率超過5%而須予披露。開發項目的地下建造工程接近完工，公司預計該項目將有助於集團資源共享及品牌影響力擴大。由於未能及時遵守上市規則第14章的通告及公告規定，公司對此深表歉意，並已採取補救措施，包括委任德勤企業諮詢進行內部控制審查。此外，公司股份自2023年11月23日起暫停買賣，待達成復牌指引。
啟明醫療-B（股份代號：2500）宣布，公司已於2021年9月通過公開招標獲得杭州市規劃和自然資源局項目土地的使用權，該土地位於杭州國家高新技術產業開發區，計劃用於開發啟明醫療生命健康產業園。2022年11月17日，啟明醫療與中建一局集團簽訂建造合約，合約總額約為人民幣11.82億元，該合約因最高適用百分比率超過5%而須予披露。開發項目的地下建造工程接近完工，公司預計該項目將有助於集團資源共享及品牌影響力擴大。由於未能及時遵守上市規則第14章的通告及公告規定，公司對此深表歉意，並已採取補救措施，包括委任德勤企業諮詢進行內部控制審查。此外，公司股份自2023年11月23日起暫停買賣，待達成復牌指引。
Kai Ming Medical -B (stock code: 2500) announced that the company has acquired the right to use the project land of the Hangzhou City Planning and Natural Resources Bureau in September 2021, which is located in the Hangzhou National High-Tech Industrial Development Zone, and is planned to be used for the development of the Ming Medical Life and Health Industry Park. On 17 November 2022, Kai Ming Medical and China Construction Group signed a construction contract with a total contract value of approximately RMB11.82 million, which is subject to disclosure due to the maximum applicable percentage exceeding 5%. The development project's underground construction is nearing completion, and the company expects the project to contribute to the Group's resource sharing and brand reach. Due...Show More
Kai Ming Medical -B (stock code: 2500) announced that the company has acquired the right to use the project land of the Hangzhou City Planning and Natural Resources Bureau in September 2021, which is located in the Hangzhou National High-Tech Industrial Development Zone, and is planned to be used for the development of the Ming Medical Life and Health Industry Park. On 17 November 2022, Kai Ming Medical and China Construction Group signed a construction contract with a total contract value of approximately RMB11.82 million, which is subject to disclosure due to the maximum applicable percentage exceeding 5%. The development project's underground construction is nearing completion, and the company expects the project to contribute to the Group's resource sharing and brand reach. Due to the failure to comply with the notices and notices provided for in Chapter 14 of the Listing Rules in a timely manner, the Company apologizes for this and has taken remedial measures, including the appointment of Dokine Corporate Advisory to conduct an internal control review. In addition, the trading of the company's shares will be suspended from 23 November 2023, pending the fulfilment of the re-licensing guidelines.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more